

- 1) Böhm, M., & Schumacher, H. (2009). Nebivolol: The evolution of a beta-blocker. *Therapeutic Advances in Cardiovascular Disease*, 3(4), 317–327.
<https://doi.org/10.1177/1753944709104496>
- 2) Jayed, D., Al-Huthi, M. A., Al-Zandani, A., Al-Shuki, S., Al-Dholae, M., & Salah, M. K. (2023). *Khat chewing induce transient elevation of blood pressure: By using 24-hour ambulatory blood pressure monitoring, in Yemen Republic*. *Open Access Library Journal*, 10, e10225. <https://doi.org/10.4236/oalib.11010225>
- 3) Mega, T. A., & Dabe, N. E. (2017). *Khat (Catha edulis) as a risk factor for cardiovascular disorders: Systematic review and meta-analysis*. *The Open Cardiovascular Medicine Journal*, 11, 146–155.
<https://doi.org/10.2174/1874192401711010146>
- 4) Manolis, A., Karakasis, P., Patoulas, D., Doumas, M., Kallistratos, M., Thomopoulos, C., Koutsaki, M., Grassi, G., & Mancia, G. (2025). Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: An updated systematic review and multilevel meta-analysis of 91 randomized controlled trials. *High Blood Pressure & Cardiovascular Prevention*, 32(1), 7–31. <https://doi.org/10.1007/s40292-024-00687-5>
- 5) Liu, J.-Y., Guo, L.-N., Peng, W.-Z., Jiang, Y., Wang, A.-L., Guo, X.-M., & Xu, Z.-S. (2020). Efficacy and safety of nebivolol in hypertensive patients: A meta-analysis of randomized controlled trials. *Journal of International Medical Research*, 48(10), 1–11. <https://journals.sagepub.com/doi/10.1177/0300060520931625>
- 6) **Sharp, R. P., & Gales, B. J. (2017). *Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction*. *Therapeutic Advances in Urology*, 9(2), 59–63. <https://doi.org/10.1177/1756287216685027>**
- 7) **Cleland, J. G. F., Tendera, M., Adamus, J., Freemantle, N., & Nikitin, N. P. (2005). The SENIORS trial: Effects of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. *European Heart Journal*, 26(3), 215–225. <https://doi.org/10.1093/eurheartj/ehi115>**
- 8) Perros, F., Ranchoux, B., Izikki, M., Bentebbal, S., Happé, C., Antigny, F., Jourdon, P., Dorfmueller, P., Lecerf, F., Fadel, E., Simonneau, G., Humbert, M., Bogaard, H. J., & Eddahibi, S. (2015). Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. *Journal of the American College of Cardiology*, 65(7), 668–680.
<https://doi.org/10.1016/j.jacc.2014.11.050>
- 9) Edes, I., Gasior, Z., & Wita, K. (2005). Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: Results of the ENECA study. *European Journal of Heart Failure*, 7(4), 631–639.
<https://doi.org/10.1016/j.ejheart.2004.10.015>

